Researchers looking for new antibiotics to tackle drug-resistant infections have signed a £3m deal with an Oxfordshire chemical company.
Evotec OAI, of Milton Park, near Abingdon, will provide chemistry skills to biotech company Prolysis, based at Begbroke Science Park, for three years.
Prolysis was set up to identify drug-like compounds that act as antibiotics.
Evotec OAI will receive fees for services as well as an equity stake in Prolysis. The deal could eventually be worth up to £7m. Prolysis will pay a fee to Evotec to gain access to over 20 man years of dedicated expert chemistry resource. Evotec, which was formed from the merger of German company with Oxford University spin-off company Oxford Asymmetry International, will apply its world-class biology, medicinal and computational chemistry skills to design and synthesise compounds against selected Prolysis targets.
Comments: Our rules
We want our comments to be a lively and valuable part of our community - a place where readers can debate and engage with the most important local issues. The ability to comment on our stories is a privilege, not a right, however, and that privilege may be withdrawn if it is abused or misused.
Please report any comments that break our rules.
Read the rules hereComments are closed on this article